Pyrotinib-based neoadjuvant therapy using a pill regimen achieved pathological response rates comparable to the standard trastuzumab–pertuzumab combination in a multicenter phase II trial in HER2-positive early breast cancer (ID: 975c696e5aaf430b). The study supports an oral, neoadjuvant option that could simplify treatment logistics while maintaining efficacy endpoints used to gauge tumor response. The trial adds to a growing effort to replace IV-heavy antibody programs with oral HER2 targeting strategies. While phase II results are not a substitute for phase III confirmation, the comparable pathologic response signal is likely to influence how future trials are designed and how clinicians consider patient preference and adherence. No regulatory action was reported, but the comparative design against trastuzumab–pertuzumab positions the regimen as an immediate contender for further development in the neoadjuvant setting.